Basically, the idea seems to be reduction in toxicity/side effects along with an angiogenic benefit..meaning lower doses more frequently may prevent cancer cells from rebuilding between doses. I get the sense that the approach has been looked at more in the context of traditional (broad) chemos. T-DM1 is such a different animal (highly targeted), I don't know if anyone's considering it applicable. Who knows..maybe that's next.
Here's a definition and brief discussion:
http://www.cancer.gov/ncicancerbulle...n_062706/page4
Here's a paper on 5 years experience at the Sunnybrooke facility mentioned in the abstract Lani posted:
http://content.karger.com/ProdukteDB...=000111479.pdf